Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

CBST 98.67 +0.90 (0.92%)
price chart
Cubist Pharmaceuticals: An Extraordinary Arbitrage Opportunity
Several news sources reported on Friday, December 5, that Cubist was in discussions to be acquired; Merck (NYSE: MRK) announced before the market opened on Monday that it had agreed to buy the company for $8.5 billion, or $102 per share, via a tender ...
In $9.5b deal, giant Merck buying Lexington's Cubist
The battle against emerging �superbugs� is producing a new generation of antibiotics. Now it has also produced a giant payout for a Lexington biotech on the front lines of the effort to take on increasingly potent bacteria.
Merck to take on superbugs with Cubist Pharma buy  Reuters
Stocks to Watch: Cubist Pharma, McDonald's, American Airlines  Wall Street Journal (blog)
Related articles »  
FDA approves Cubist's Zerbaxa
The FDA has approved the use of Cubist's (NASDAQ:CBST) Zerbaxa (ceftolozane/tazobactam) for "the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by designated susceptible ...
FDA Approves Cubist's Experimental Antibiotic Zerbaxa  Wall Street Journal
Merck Begins Tender Offer to Acquire Cubist  MarketWatch
Related articles »  
Merck & Co. (MRK) Seeks $8 Billion Bridge Loan To Acquire Cubist ...
Merck, the second-largest US pharmaceutical player behind Pfizer Inc. (NYSE:PFE), has chosen to stick to its decision to acquire Cubist, possibly because Cubist could have likely slapped the company with a lawsuit if Merck had got cold feet upon the ...
Merck looks for US$8bn bridge for Cubist acquisition  IFR Asia
Related articles »  
Cubist soars on Merck's $8.4b purchase
Inc. said last week it will proceed with its planned $8.4 billion purchase of Lexington's Cubist Pharmaceuticals Inc. and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of ...
Related articles »  
PDUFA date approaches for Cubist antibiotic combo (CBST)
The FDA's PDUFA date for its Fast Track/Priority Review of Cubist Pharmaceuticals' (CBST) New Drug Application (NDA) for its combination drug, ceftolozane/tazobactam, for the treatment of complicated urinary tract infections is December 21.
Cubist Pharmaceuticals Inc (NASDAQ:CBST) Downgraded at UBS  Street Report
Cubist Pharmaceuticals Given "BBB-" Credit Rating (CBST)  Watch List News
Related articles »  
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky ...
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cubist Pharmaceuticals, Inc. (�Cubist� or the �Company�) (NASDAQ GS: CBST) regarding possible breaches of fiduciary duties and other ...
Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc.
NEW YORK, Dec. 8, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cubist Pharmaceuticals Inc. ("Cubist" or the "Company") (NASDAQ: CBST) concerning the proposed acquisition ...
Benzinga's Weekend M&A Chatter  Benzinga
Related articles »  
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT:Former SEC ...
DALLAS, Dec 08, 2014 (BUSINESS WIRE) -- Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cubist ...
Related articles »  
Why Louisiana-Pacific, Best Buy, and Cubist Pharmaceuticals are 3 of Today's ...
However, bucking the bearishness today were Louisiana-Pacific Corporation (LPX), Best Buy Co Inc (BBY), and Cubist Pharmaceuticals Inc (CBST), all up sharply and looking strong throughout the day. Here's why those three were able to overcome the ...